Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Non Operating Income: 2019-2025

Historic Non Operating Income for Avidity Biosciences (RNA) over the last 7 years, with Sep 2025 value amounting to $14.4 million.

  • Avidity Biosciences' Non Operating Income fell 19.01% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.7 million, marking a year-over-year increase of 41.78%. This contributed to the annual value of $56.6 million for FY2024, which is 142.25% up from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' Non Operating Income is $14.4 million, which was up 3.88% from $13.8 million recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' Non Operating Income peaked at $18.7 million during Q4 2024, and registered a low of -$95,000 during Q4 2021.
  • For the 3-year period, Avidity Biosciences' Non Operating Income averaged around $11.3 million, with its median value being $11.8 million (2024).
  • In the last 5 years, Avidity Biosciences' Non Operating Income plummeted by 627.78% in 2021 and then spiked by 12,190.91% in 2022.
  • Over the past 5 years, Avidity Biosciences' Non Operating Income (Quarterly) stood at -$95,000 in 2021, then soared by 2,998.95% to $2.8 million in 2022, then soared by 128.76% to $6.3 million in 2023, then spiked by 197.35% to $18.7 million in 2024, then decreased by 19.01% to $14.4 million in 2025.
  • Its Non Operating Income stands at $14.4 million for Q3 2025, versus $13.8 million for Q2 2025 and $15.7 million for Q1 2025.